Accel Wealth Management Has $1.09 Million Position in Johnson & Johnson (NYSE:JNJ)

Accel Wealth Management lessened its stake in Johnson & Johnson (NYSE:JNJ) by 1.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,561 shares of the company’s stock after selling 96 shares during the period. Accel Wealth Management’s holdings in Johnson & Johnson were worth $1,088,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Apella Capital LLC lifted its position in Johnson & Johnson by 13.6% during the 1st quarter. Apella Capital LLC now owns 27,649 shares of the company’s stock valued at $4,174,000 after purchasing an additional 3,314 shares during the period. Bremer Bank National Association lifted its holdings in Johnson & Johnson by 11.8% in the first quarter. Bremer Bank National Association now owns 2,979 shares of the company’s stock valued at $494,000 after buying an additional 314 shares during the period. Silverberg Bernstein Capital Management LLC raised its position in shares of Johnson & Johnson by 3.4% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 9,000 shares of the company’s stock valued at $1,493,000 after acquiring an additional 300 shares during the last quarter. Spring Capital Management LLC lifted its stake in shares of Johnson & Johnson by 0.3% in the 1st quarter. Spring Capital Management LLC now owns 45,062 shares of the company’s stock valued at $7,473,000 after purchasing an additional 130 shares during the period. Finally, Whipplewood Advisors LLC boosted its position in shares of Johnson & Johnson by 5.3% in the 1st quarter. Whipplewood Advisors LLC now owns 1,636 shares of the company’s stock worth $295,000 after purchasing an additional 82 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.6%

NYSE JNJ opened at $154.45 on Wednesday. The company has a market cap of $371.63 billion, a PE ratio of 23.23, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a 50 day moving average of $154.01 and a 200-day moving average of $153.68. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.37%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Raymond James reduced their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Morgan Stanley increased their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 16th. Finally, Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.